JPH04501719A - ポリペプチド - Google Patents

ポリペプチド

Info

Publication number
JPH04501719A
JPH04501719A JP1511698A JP51169889A JPH04501719A JP H04501719 A JPH04501719 A JP H04501719A JP 1511698 A JP1511698 A JP 1511698A JP 51169889 A JP51169889 A JP 51169889A JP H04501719 A JPH04501719 A JP H04501719A
Authority
JP
Japan
Prior art keywords
item
items
cells
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1511698A
Other languages
English (en)
Japanese (ja)
Inventor
テイラー―パパデイミトリオウ，ジヨイス
ジエンドラー，サンドラ
バーチエル，ジヨイ
Original Assignee
インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888826362A external-priority patent/GB8826362D0/en
Priority claimed from GB898907660A external-priority patent/GB8907660D0/en
Application filed by インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド filed Critical インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Publication of JPH04501719A publication Critical patent/JPH04501719A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP1511698A 1988-11-10 1989-11-10 ポリペプチド Pending JPH04501719A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB888826362A GB8826362D0 (en) 1988-11-10 1988-11-10 Polypeptide
GB8826362.9 1988-11-10
GB898907660A GB8907660D0 (en) 1989-04-05 1989-04-05 Polypeptide
GB8907660.8 1989-04-05

Publications (1)

Publication Number Publication Date
JPH04501719A true JPH04501719A (ja) 1992-03-26

Family

ID=26294608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1511698A Pending JPH04501719A (ja) 1988-11-10 1989-11-10 ポリペプチド

Country Status (3)

Country Link
EP (1) EP0442926A1 (fr)
JP (1) JPH04501719A (fr)
WO (1) WO1990005142A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
ATE160361T1 (de) * 1987-01-07 1997-12-15 Imp Cancer Res Tech Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
JP3698370B2 (ja) * 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1995027505A1 (fr) * 1994-04-12 1995-10-19 Biomira, Inc. Antigenes specifiques d'une reponse immunitaire cellulaire et leurs utilisations
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
WO1997035008A1 (fr) * 1996-03-21 1997-09-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et composition de polypeptides chimeres pour des vaccins antigeniques tumoraux
GB9717946D0 (en) * 1997-08-22 1997-10-29 Imp Cancer Res Tech Novel chemical entity
ES2322212T3 (es) 1997-09-29 2009-06-17 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Composicion de antigeno y linea celular que lleva el receptor manosa.
EP1369428A1 (fr) * 1997-10-31 2003-12-10 Biomira Inc. Dérivés de Muc-1 et leur utilisation dans le traitement d'immunosupression induite par le MUC-1 Mucin associé au cancer
ATE338768T1 (de) * 1997-10-31 2006-09-15 Biomira Inc Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2396343B1 (fr) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
WO2011088081A1 (fr) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Répétitions terminales inversées restrictives pour vecteurs viraux
JP6042825B2 (ja) 2011-02-10 2016-12-14 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
EP3738974A1 (fr) 2012-09-28 2020-11-18 The University of North Carolina at Chapel Hill Vecteurs vaa ciblés sur des oligodendrocytes
EP3838297A1 (fr) 2013-03-15 2021-06-23 The University of North Carolina at Chapel Hill Méthodes et compositions de double liaison de glycane de vecteurs avv
EP3517612A1 (fr) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
MX2017006652A (es) 2014-11-21 2017-08-21 Univ North Carolina Chapel Hill Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central.
EP3245220B1 (fr) 2015-01-14 2023-09-20 The University of North Carolina at Chapel Hill Procédés et compositions destinés au transfert de gènes ciblé
EP3611186A1 (fr) 2015-02-06 2020-02-19 The University of North Carolina at Chapel Hill Cassettes optimisées d'expression génétique du facteur viii de coagulation humain et leur utilisation
WO2016134300A1 (fr) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Méthodes et compositions permettant d'utiliser la chlamydia atténuée en tant que vaccin et vecteur
SG10202107733QA (en) 2015-09-28 2021-09-29 Univ North Carolina Chapel Hill Methods and compositions for antibody-evading virus vectors
SG11201804197RA (en) 2015-11-18 2018-06-28 Orbis Health Solutions Llc T7 alpha viral vector system
AU2018234695A1 (en) 2017-03-15 2019-09-12 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
MX2020010466A (es) 2018-04-03 2021-01-08 Vectores de virus que evitan anticuerpos.
CN112533644A (zh) 2018-04-03 2021-03-19 斯特里迪比奥公司 靶向眼组织的病毒载体
WO2019195449A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs de virus évitant les anticorps
EP3810782A2 (fr) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vecteurs pour l'administration de gènes qui persistent dans les cellules
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
CN113767110A (zh) 2019-04-26 2021-12-07 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
WO2021076925A1 (fr) 2019-10-17 2021-04-22 Stridebio, Inc. Vecteurs de virus adéno-associés pour le traitement de la maladie de niemann-pick de type c
JP2023547992A (ja) 2020-10-28 2023-11-15 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
WO2022093769A1 (fr) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
WO2022221529A1 (fr) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Virions de vaa à polyploïde rationnel traversant la barrière hémato-encéphalique et déclenchant une réponse humorale réduite
WO2023150687A1 (fr) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Vecteurs viraux adéno-associés recombinants et méthodes d'utilisation associées
WO2024124019A2 (fr) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Vecteurs aav ciblant des cellules souches hématopoïétiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160361T1 (de) * 1987-01-07 1997-12-15 Imp Cancer Res Tech Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose

Also Published As

Publication number Publication date
EP0442926A1 (fr) 1991-08-28
WO1990005142A1 (fr) 1990-05-17

Similar Documents

Publication Publication Date Title
JPH04501719A (ja) ポリペプチド
US11447536B2 (en) High avidity antigen recognizing constructs
US6344203B1 (en) Mimicking peptides in cancer therapy
ES2240981T3 (es) Citocina denominada lerk-7.
ES2652017T3 (es) Métodos y composiciones farmacéuticas para el engaño inmunitario, particularmente útiles en el tratamiento de cáncer
US9452204B2 (en) Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes
US7268207B2 (en) Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
JPH09501159A (ja) 合成多重縦列反復ムチンおよびムチン様ペプチド、並びにそれらの利用
EA030777B1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
JPH09505723A (ja) ４３ｋｄヒトガン抗原からの免疫反応性ペプチド配列
US7358087B2 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
Insug et al. Role of SA–Lea and E-selectin in metastasis assessed with peptide antagonist
WO2011091716A1 (fr) Variante du récepteur du facteur de croissance épidermique
Liang et al. Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxy group
CN1082053A (zh) 合成多肽
EP1167387A1 (fr) Anticorps anti-SEMP1, procédé pour leur production, et leurs utilisations
US20240182577A1 (en) Anti-pd-1 signal peptide antibody and use thereof
JP2005513040A (ja) Ｔｌｐペプチドを含む融合タンパク質
US20050063970A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
JP4037451B2 (ja) 大腸細胞および大腸癌細胞関連核酸分子、タンパク質およびペプチド
CN1668640A (zh) 肿瘤标志物及其用途
CN1622955A (zh) 肿瘤标志物及其用途
WO2005014819A1 (fr) Antigene du cancer de l'oesophage et utilisation de celui-ci
WO2000020442A1 (fr) Peptides antigenes specifiques aux tumeurs